Healthcare · Biotechnology · NASDAQ

Viridian Therapeutics Inc (VRDN) Stock Price, Analysis & Trade Signals

$29.96-1.48 (-4.71%)

Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen…

VRDN key stats

Market Cap
$3.4B
P/E Ratio
0
Forward P/E
1.01
EPS
-3.85
52 Week Range
$13.18 – $34.29
50-Day Avg
23.53
200-Day Avg
21.52
Revenue (TTM)
$26.31M
Revenue Growth (Qtr YoY)
-63.5%
Profit Margin
0%
Operating Margin (TTM)
-1781%
Beta
1.07
Volume
1.75M
30-Day Avg Volume
2.85M
CEO
Stephen F. Mahoney
Employees
252
IPO Date
Jun 18, 2014

VRDN on X: what traders are saying

  • HODOR @Maximus_Holla · Nov 6, 2026

    $VRDN Data NOV 9th for VRDN-008! https://t.co/YFPIJ1TSXq https://t.co/eGtV8HYDCQ

  • HODOR @Maximus_Holla · Nov 4, 2026

    $VRDN "We are highly encouraged by the strength of Lumvoa's early launch in TED, which has exceeded expectations," said Steve Mahoney, President and Chief Executive Officer of Viridian Therapeutics. "These strong early results are a testament to Lumvoa's compelling clinical…

  • HODOR @Maximus_Holla · Nov 4, 2026

    $VRDN big ER! https://t.co/UhlZJySaxH https://t.co/j09kM90E4J

  • HODOR @Maximus_Holla · Nov 3, 2026

    $VRDN 26 holla! https://t.co/plKwDuedoU https://t.co/j09kM90E4J

  • HODOR @Maximus_Holla · Oct 29, 2026

    $VRDN great so far! 26.28 Gap fill next! https://t.co/QwzIozOlCc https://t.co/KWumam0KNN

  • HODOR @Maximus_Holla · Oct 27, 2026

    $VRDN 25 next level! https://t.co/E1VEdBrEkk https://t.co/VYJ4xeZnw1

VRDN analyst rating & price target

17 analysts rate VRDN Buy on consensus.

3Strong Buy
14Buy
0Hold
0Sell
0Strong Sell

Consensus price target: $36.75 (+22.66% upside from $29.96)

Recent VRDN insider transactions

InsiderDateTransactionSharesValue
Tousignant Jennifer
Chief Legal Officer
Aug 19, 2026Sale10,000$245K
Fairmount Funds Management LLC
director, 10 percent owner:
May 11, 2026Purchase1,176,470$20M
Tousignant Jennifer
Chief Legal Officer
Dec 31, 2025Sale2,272$70.8K

Viridian Therapeutics Inc annual revenue & net income

Fiscal yearRevenueRevenue YoYNet income
2025$70.85M+23359.93%$-342.6M
2024$302K-3.82%$-269.95M
2023$314K-82.28%$-237.73M

Stock data for VRDN: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics